Recently, two studies have evaluated T-DXd-induced ILD: phase 1b/2 DESTINY-Breast07 (NCT04538742) in advanced or metastatic HER2-positive BC patients and phase 1 b DESTINY-Breast08 (NCT04556773) in HER2-low BC. Here, ERBB2 is linked to breast cancer.